• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Reforming Oncology Care Payments: Interviews From the QCCA Leadership Summit

News
Podcast

As the costs of cancer care continue to rise in the United States, eyes are increasingly turning to payment reform.

As the costs of cancer care continue to rise in the United States, eyes are increasingly turning to payment reform. Research by the Northeast Business Group on Health found that in 2015, employers spent $125 million on cancer care, and since then, cancer therapy costs have increased substantially with greater use of immunotherapy and the introduction of chimeric antigen receptor T-cell therapies that can easily cost half a million dollars for treatment.

The federal government is taking the lead with the Oncology Care Model, which will transition into Oncology Care First in 2022 after a 1-year extension due to the coronavirus disease 2019 pandemic, but commercial payers are also testing payment reform models.

Speakers who participated in the Quality Cancer Care Alliance’s Fall Leadership Summit weighed in on the payment reform space for cancer care.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Read more:

Speaking of Employers: Purchasers Detail the Challenges of Getting a Handle on Oncology Care Costs

Three Ways COVID-19 Makes the Oncology Care First Model More Attractive

Infrastructure of OCM Helps Practices Through COVID-19, Chong Says

A Closer Look at 3 Oncology Payment Reform Projects

Cancer Does Not Stop for COVID-19, but Reform Becomes a Challenge

Community Oncology Alliance Payment Reform Brief Details 35 Oncology Payment Models Underway or Planned Across Country

Related Videos
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster - stock.adobe.com
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Robert Zimmerman, MD
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.